Semaglutide is a long-acting analog of a naturally occurring hormone in the body (GLP-1) and was FDA approved in 2021 for the treatment of obesity and well as readily prescribed for the treatment of diabetes since 2017.
Semaglutide is not recommended for those who have ever had (or have a family history of) a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you (or a member of your family) have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Semaglutide is also not recommended for those who have had a serious allergic reaction to Semaglutide or any of the ingredients in semaglutideTM. Semaglutide is not recommended for those with Type I diabetes.
There are rarely side effects reported while using Semaglutide for weight loss. The most common reported side effect is light nausea, but dosage adjustments can be made to help reduce those effects throughout treatment.